Estrella Immunopharma, Inc.: Form 10-KT, filed Mar 25, 2025
Filed with the SEC on Mar 25, 2025 and accepted by EDGAR at Mar 25, 2025, 16:30 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 6 months2024-07-01 to 2024-12-31 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 6 months2024-07-01 to 2024-12-31 | −$4.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months2024-07-01 to 2024-12-31 | $63 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 6 months2024-07-01 to 2024-12-31 | −$4.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 6 months2024-07-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 6 months2024-07-01 to 2024-12-31 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 6 months2024-07-01 to 2024-12-31 | 36,515,688 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-07-01 to 2024-12-31 | −$3.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-12-31 | $916.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $1.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $3.1m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $3.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $3.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $143.7k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001013762-25-002190. Last ingested by Listed: Nov 4, 2026, 07:37 ET. Listed shows no prices and gives no investment advice.